Premium
New Drug Interactions with Zidovudine
Author(s) -
RobertsonDallas Shan,
Read Stanley E.,
Bendayan Reina
Publication year - 1997
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1997.tb03083.x
Subject(s) - zidovudine , drug , polypharmacy , medicine , human immunodeficiency virus (hiv) , antiretroviral drug , pharmacotherapy , pharmacology , drug interaction , population , antiretroviral therapy , virology , viral disease , viral load , environmental health
Polypharmacy is commonly encountered in human immunodeficiency virus (HIV)‐positive patients, and the risk and frequency of drug‐drug interactions are significant in this patient population. Most HIV‐positive patients receive the antiretroviral drug zidovudine (3′‐azido‐3′‐deoxythymidine, ZDV), the first drug to be approved for the treatment of HIV Many drug interactions with ZDV have already been reported. As HIV pharmacotherapy becomes more complex, the potential for drug‐drug interactions is likely to increase significantly.